Dr. Sumanta K. Pal on cabozantinib in papillary RCC
In the phase 2 SWOG 1500 study, cabozantinib (Cabometyx) significantly improved progression-free survival versus sunitinib (Sutent) in patients with metastatic papillary renal cell carcinoma.
Sumanta K. Pal, MD, FASCO, medical oncologist and assistant clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses results of the phase 2 SWOG 1500 study presented during the 2021 Genitourinary Cancers Symposium. The study showed that cabozantinib (Cabometyx) reduced the risk of disease progression or death by 40% compared with sunitinib in patients with metastatic papillary renal cell carcinoma. The median PFS with cabozantinib was 9.0 months versus 5.6 months with sunitinib (HR, 0.60; P = .019). The response rates were 23% versus 4.0%, respectively (J Clin Oncol. 2021;339[suppl 6]:270. doi:10.1200/JCO.2021.39.6_suppl.270).
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
